On 14 December, AlzeCure Pharma AB, a Swedish pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, announced that is has begun a preclinical development phase with its drug candidate ACD857 for Alzheimer's disease (AD). This preclinical development program includes preclinical safety and tolerability studies, formulation work and stability testing. ACD857 is derived from the NeuroRestore platform, with the aim of developing symptom-relieving drugs for cognitive disorders.
The company has recently announced that it has received approval to initiate a Phase I clinical trial with ACD856, another therapy candidate for AD, in Sweden.
